How to demonstrate the bioequivalence of sulodexide [Design Issues]

posted by bjkim97  – Korea / Seoul, 2018-05-30 08:41 (1337 d 14:16 ago) – Posting: # 18828
Views: 1,888

We are planning to development of the sulodexide.

As far as I Know, this product does not have accurate guldelines and design.

So I have reviewed several documents. The FDA and EMEA have identified guidelines for LMWH.

The sulodexide is defined as follows.

Sulodexide is highly purifuled mixture of glycosaminoglycans composed of FMH (Fast Moving Heparin) (80%) and Dermatan sulfate (20%).

I will refer to the FDA enoxaparin recommend guidelines for pharmacodynamic equivalence.

Just one question:
I am not sure if enoxaparin recommendations can be applied to Sulodexide.

I want to hear your opinion. Please give me your opinion



Complete thread:

 Admin contact
21,854 posts in 4,573 threads, 1,554 registered users;
online 13 (0 registered, 13 guests [including 11 identified bots]).
Forum time: Wednesday 21:57 CET (Europe/Vienna)

The real purpose of the scientific method is to make sure
nature hasn’t misled you into thinking you know something
you actually don’t know.    Robert M. Pirsig

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz